1. Scrip
  2. >>Business
  3. >>Financing

Kinnate Raises $98m To Take Kinase Inhibitors Into The Clinic

The Series C Round Brings Fundraising Total To $192.5m

 
• By Mandy Jackson

The company’s next-generation kinase inhibitors are designed to target unaddressed mutations and overcome treatment resistance. Lead programs focus on BRAF Class II and III mutations and FGFR2/3.

SC2008_Financial Investment_ 312188576_1200.jpg
Kinnate's new funding will help it grow from 25 to 50 employees • Source: Shutterstock

Kinnate Biopharma Inc. CEO Nima Farzan notes that while about 10% of cancer patients are eligible for treatment with a targeted oncology drug only half respond to treatment and about half of the responders will develop resistance. With the goal of effectively treating more patients with targeted therapeutics, his company revealed a $98m series C venture capital round on 26 August to take its first two drugs designed to inhibit new targets and overcome treatment resistance into the clinic.

“Only a few percent of overall cancer patients are effectively, in the long term, treated with targeted therapies; we see this as a tremendous

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Hengrui Set For Biggest Biopharma IPO So Far This Year

 
• By Dexter Jie Yan

Jiangsu Hengrui Pharmaceuticals is gearing up for what will be 2025's biggest biopharma IPO so far, hoping to raise up to $1.27bn on the Hong Kong Stock Exchange. China's top drug maker by pipeline size plans to use part of the proceeds to reboot its overseas clinical trials ambitions.

Finance Watch: Funding Alternatives Become The Norm In Tough Public Markets

 
• By Mandy Jackson

Public Company Edition: With fewer follow-on offerings, drug developers are pursuing other options. Axsome accessed up to $570m in debt, Evolus obtained $250m in a new credit facility and Abeona raised $155m from a PRV sale, but Apimeds was able to execute a small $13.5m IPO.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

More from Business

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

 
• By Anju Ghangurde

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.